On June 24th, Zhiyun Health announced that it has successfully obtained exclusive sub-licensing permission for the injection of iloprost solution and will be fully responsible for the commercial operation of the product in Greater China (including mainland China, Hong Kong, and Macau). With the platform advantages formed by the hospital SaaS system and the pharmacy SaaS system, as well as professional digital promotion capabilities, Zhiyun Health will strive to improve drug accessibility and benefit more than one million domestic pulmonary arterial hypertension patients.

Pulmonary arterial hypertension refers to the clinical and pathological physiological syndrome caused by changes in pulmonary vascular structure or function due to various heterogeneous diseases and different pathogeneses, resulting in increased pulmonary vascular resistance and pulmonary arterial pressure. It is estimated that the number of pulmonary arterial hypertension patients in China exceeds 5 million, of which 1.3-2.07 million are NYHA III-IV level patients. Most patients lack treatment or face heavy economic burden, seriously affecting patients' quality of life and life expectancy, and urgently need effective treatment methods to improve their conditions.

Iloprost, as one of the internationally used clinical targeted drugs, is a prostacyclin analogue that has been proven to have significant efficacy in cardiovascular diseases such as pulmonary arterial hypertension. Studies have shown that iloprost can rapidly reduce pulmonary vascular resistance and increase cardiac output in patients with pulmonary arterial hypertension, and long-term use of iloprost can improve the 2-year survival rate of pulmonary arterial hypertension patients to 87%. The drug has mild adverse reactions and good tolerance. Since its injection type was first launched in 2001, iloprost injection has become one of the important drugs for the treatment of pulmonary arterial hypertension and other diseases in many countries worldwide. However, in the domestic market, the choice of similar drugs is relatively limited. As the only generic drug of its kind in world, the injection of iloprost solution has not yet been launched in the domestic market with similar content and belongs to exclusive formulation that will effectively fill the domestic market gap.

It is reported that the classification of injection iloprost solution is 5.2 in drug registration, which can be attributed to the use of orphan disease (IPAH), which has the opportunity to enjoy the "priority review and approval procedure", with a short listing cycle and expected to benefit patients as soon as possible. In addition to pulmonary arterial hypertension, the indications of iloprost injection solution are expected to continue to expand to the fields of thromboangiitis obliterans TAO, Raynaud's phenomenon RP, and PAOD in the future, opening up more growth space for products in the field of cardiovascular disease treatment.

Injection of iloprost solution has become one of the important drugs for the treatment of pulmonary arterial hypertension and other diseases in many countries worldwide since its injection type was first launched in 2001. However, in the domestic market, the choice of similar drugs is relatively limited. As the only generic drug of its kind in world, the injection of iloprost solution has not yet been launched in the domestic market with similar content and belongs to exclusive formulation that will effectively fill the domestic market gap.

It is worth noting that as a field with a large number of patients and unsatisfactory treatment, the global pulmonary arterial hypertension treatment market is expected to reach 11 billion U.S. dollars by 2030, attracting many global pharmaceutical giants to get involved, such as Merck, which spent $11.5 billion to acquire Acceleron in 2021, obtaining WinrevairTM (sotatercept), a treatment for pulmonary arterial hypertension, which was approved by the FDA in March. China has also maintained a relatively fast market growth in the field of pulmonary arterial hypertension in recent years, and is expected to maintain a compound annual growth rate of more than 30% over the next 3-5 years.

As a leading domestic digital health management platform, Zhiyun Health has long been committed to providing patients with more convenient and efficient medical products and services through technological innovation and resource integration. Obtaining exclusive sub-licensing permission for the injection of iloprost solution is an important initiative for Zhiyun Health to lay out the pulmonary arterial hypertension market of this 10-billion-yuan level, marking another solid step for Zhiyun Health in achieving the "from patient to industry" (P2M) strategy, and is expected to continue to enhance the company's profitability and differentiation competitiveness.

In the future, Zhuyun Health will actively explore innovative business models on the basis of consolidating existing advantageous business foundations, continuously carry out forward-looking layouts oriented to clinical needs of patients, and strive to popularize more high-quality products and services for the majority of patients. At the same time, Zhuyun Health will also work with various partners to jointly promote the development of the domestic medical industry and create more health benefits for the vast number of patients.

Source: Zhiyun Health Technology Group official WeChat account.